RU2474586C2 - Эффективные аналоги компстатина - Google Patents

Эффективные аналоги компстатина Download PDF

Info

Publication number
RU2474586C2
RU2474586C2 RU2008126232/04A RU2008126232A RU2474586C2 RU 2474586 C2 RU2474586 C2 RU 2474586C2 RU 2008126232/04 A RU2008126232/04 A RU 2008126232/04A RU 2008126232 A RU2008126232 A RU 2008126232A RU 2474586 C2 RU2474586 C2 RU 2474586C2
Authority
RU
Russia
Prior art keywords
tryptophan
peptide
seq
trp
compstatin
Prior art date
Application number
RU2008126232/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2008126232A (ru
Inventor
Джон Д. ЛЭМБРИЗ
Мадан КАТРАГАДДА
Original Assignee
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания filed Critical Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания
Publication of RU2008126232A publication Critical patent/RU2008126232A/ru
Application granted granted Critical
Publication of RU2474586C2 publication Critical patent/RU2474586C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
RU2008126232/04A 2005-11-28 2006-11-28 Эффективные аналоги компстатина RU2474586C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74020505P 2005-11-28 2005-11-28
US60/740,205 2005-11-28
PCT/US2006/045539 WO2007062249A2 (en) 2005-11-28 2006-11-28 Potent compstatin analogs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2012147267A Division RU2656102C2 (ru) 2005-11-28 2012-11-06 Эффективные аналоги компстатина

Publications (2)

Publication Number Publication Date
RU2008126232A RU2008126232A (ru) 2010-01-10
RU2474586C2 true RU2474586C2 (ru) 2013-02-10

Family

ID=37964706

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2008126232/04A RU2474586C2 (ru) 2005-11-28 2006-11-28 Эффективные аналоги компстатина
RU2012147267A RU2656102C2 (ru) 2005-11-28 2012-11-06 Эффективные аналоги компстатина

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2012147267A RU2656102C2 (ru) 2005-11-28 2012-11-06 Эффективные аналоги компстатина

Country Status (16)

Country Link
US (5) US7888323B2 (zh)
EP (4) EP2377877B1 (zh)
JP (2) JP5302004B2 (zh)
CN (3) CN101400692B (zh)
BR (1) BRPI0619023B1 (zh)
CA (2) CA2631443C (zh)
DK (1) DK1960422T3 (zh)
ES (3) ES2677619T3 (zh)
HK (1) HK1124621A1 (zh)
HR (1) HRP20120621T1 (zh)
IL (2) IL191674A (zh)
PL (1) PL1960422T3 (zh)
PT (1) PT1960422E (zh)
RS (1) RS52429B (zh)
RU (2) RU2474586C2 (zh)
WO (1) WO2007062249A2 (zh)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10035822B2 (en) 2012-11-15 2018-07-31 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
US10125171B2 (en) 2011-05-11 2018-11-13 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
US10308687B2 (en) 2013-03-15 2019-06-04 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
US10407466B2 (en) 2005-10-08 2019-09-10 Apellis Pharmaceuticals, Inc. Methods of selecting compstatin mimetics
US11040107B2 (en) 2017-04-07 2021-06-22 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
US11338013B2 (en) 2016-10-17 2022-05-24 Apellis Pharmaceuticals, Inc. Combination therapy for C3 inhibition
US11510939B1 (en) 2019-04-19 2022-11-29 Apellis Pharmaceuticals, Inc. RNAs for complement inhibition
US11903994B2 (en) 2015-10-07 2024-02-20 Apellis Pharmaceuticals, Inc. Dosing regimens

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1549333T1 (sl) * 2002-09-20 2012-02-29 Univ Pennsylvania Analogi kompstatina z izboljĺ ano aktivnostjo
PT1960422E (pt) * 2005-11-28 2012-08-16 Univ Pennsylvania Análogos de compstatina potentes
US8637325B2 (en) * 2009-02-16 2014-01-28 University Of Wyoming Method and apparatus for pyrolysis-induced cleavage in peptides and proteins
EP2083841B1 (en) * 2006-10-20 2013-11-20 Celldex Therapeutics, Inc. SOLUBLE COMPLEMENT RECEPTOR TYPE I (sCR1) PROTEIN FOR USE IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER DISEASES OF THE EYE
EP2979729A3 (en) * 2007-02-05 2016-05-11 Apellis Pharmaceuticals, Inc. Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system
JP2009003429A (ja) * 2007-05-18 2009-01-08 Panasonic Corp アクチュエータ
US8442776B2 (en) 2007-06-08 2013-05-14 The Trustees Of The University Of Pennsylvania Structure of compstatin-C3 complex and use for rational drug design
US8563259B2 (en) 2007-06-29 2013-10-22 The Trustees Of The University Of Pennsylvania Complement-mediated thrombophilic assay
CN101854916A (zh) * 2007-10-02 2010-10-06 博泰迪亚制药公司 由凝胶持续递送坎普他汀类似物
US20110190221A1 (en) * 2008-03-28 2011-08-04 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
WO2010039690A1 (en) * 2008-09-30 2010-04-08 The Trustees Of The University Of Pennsylvania Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
HUE035378T2 (en) * 2009-05-01 2018-05-02 Univ Pennsylvania Compstatin with peptide framework and C-terminal modifications
US20110104154A1 (en) 2009-10-30 2011-05-05 Alcon Research, Ltd. Single nucleotide polymorphisms and genes associated with age-related macular degeneration
US9358266B2 (en) 2010-02-25 2016-06-07 The Trustees Of The University Of Pennsylvania Treatment of sepsis using complement inhibitors
WO2011163394A2 (en) 2010-06-22 2011-12-29 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
CA2813049A1 (en) 2010-09-23 2012-03-29 The Trustees Of The University Of Pennsylvania Modified compstatin with improved stability and binding properties
CN103370083B (zh) * 2010-09-28 2016-11-16 艾米琳制药有限责任公司 具有增强的作用持续时间的工程化多肽
WO2012095519A1 (en) 2011-01-13 2012-07-19 Leibniz-Institut Für Naturstoff-Forschung Und Infektionsbiologie Potent inhibitors of complement activation
US20140219999A1 (en) 2011-04-01 2014-08-07 The Trustees Of The University Of Pennsylvania Treatment of colon cancer using complement inhibitors
WO2012162215A1 (en) 2011-05-20 2012-11-29 The Trustees Of The University Of Pennsylvania Promotion of fracture healing using complement inhibitors
WO2012174055A1 (en) 2011-06-13 2012-12-20 The Trustees Of The University Of Pennsylvania Wound healing using complement inhibitors
CN103796667A (zh) 2011-06-22 2014-05-14 艾普莱斯制药公司 用补体抑制剂治疗慢性障碍的方法
JP6249949B2 (ja) * 2011-09-07 2017-12-20 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 薬物動態特性の改善されたコンプスタチンアナログ
WO2014028861A1 (en) * 2012-08-17 2014-02-20 Apellis Pharmaceuticals, Inc. Detection of high risk drusen
WO2014078734A2 (en) * 2012-11-15 2014-05-22 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
WO2014100407A1 (en) * 2012-12-19 2014-06-26 The Regents Of The University Of California Compstatin analogs
IL282401B (en) 2013-12-12 2022-08-01 Alnylam Pharmaceuticals Inc Complementary component irna compositions and methods for using them
WO2015142701A1 (en) 2014-03-17 2015-09-24 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved potency and pharmacokinetic properties
US10597582B2 (en) 2014-12-23 2020-03-24 Multi-Chem Group, Llc Acrylate-based sulfur scavenging agents for use in oilfield operations
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
AU2018227849B2 (en) 2017-03-01 2022-04-28 Achillion Pharmaceuticals, Inc. Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
US11866701B2 (en) 2017-11-01 2024-01-09 Alnylam Pharmaceuticals, Inc. Complement component C3 iRNA compositions and methods of use thereof
KR20200135797A (ko) * 2018-02-27 2020-12-03 제트피 에스피브이 3 케이/에스 콤프스타틴 유사체 및 이들의 의학적 용도
US11884747B2 (en) 2018-04-06 2024-01-30 The Trustees Of The University Of Pennsylvania Compstatin analogs with increased solubility and improved pharmacokinetic properties
KR20210057086A (ko) 2018-09-06 2021-05-20 아칠리온 파르마세우티칼스 인코포레이티드 다니코판의 형태체 형태
WO2020051532A2 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
CN112996497A (zh) 2018-09-25 2021-06-18 艾其林医药公司 补体因子d抑制剂的形态形式
KR20220066287A (ko) 2019-08-27 2022-05-24 제트피 에스피브이 3 케이/에스 콤프스타틴 유사체 및 이의 의약 용도
WO2021081026A1 (en) 2019-10-22 2021-04-29 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof
WO2021178607A1 (en) 2020-03-05 2021-09-10 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
IL297680A (en) 2020-04-30 2022-12-01 Alnylam Pharmaceuticals Inc IRNA compounds complement factor b (cfb) and methods of using them
EP4149473A1 (en) 2020-05-12 2023-03-22 Alexion Pharmaceuticals, Inc. Use of complement factor d inhibitors alone or in combination with anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria
CN116209671A (zh) 2020-07-16 2023-06-02 西兰制药第三特殊目的公司 补体因子c3的抑制剂及其医学用途
WO2022150260A1 (en) 2021-01-05 2022-07-14 Alnylam Pharmaceuticals, Inc. COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2023044370A2 (en) 2021-09-17 2023-03-23 Alnylam Pharmaceuticals, Inc. Irna compositions and methods for silencing complement component 3 (c3)
WO2023076451A1 (en) 2021-10-29 2023-05-04 Alnylam Pharmaceuticals, Inc. Complement factor b (cfb) irna compositions and methods of use thereof
CN114605495A (zh) * 2022-04-20 2022-06-10 广州市乾相生物科技有限公司 一种乳四肽的合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004026328A1 (en) * 2002-09-20 2004-04-01 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved activity
RU2238322C2 (ru) * 1996-03-07 2004-10-20 Имутран Лимитед Протеин, обладающий способностью к образованию с3-конвертазы, днк, вектор, конъюгат и их использование

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2295746A1 (fr) 1974-12-23 1976-07-23 Francaise Coop Pharma Nouveaux derives du tryptophane a activite nerveuse centrale renforcee
IT1179866B (it) * 1984-12-12 1987-09-16 Rotta Research Lab Derivati del triptofano farmaceuticamente attivi e composizioni farmaceutiche che li contengono
US4576750A (en) 1985-04-22 1986-03-18 Merck & Co., Inc. Tryptophan derivative
US5256642A (en) * 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
US5167960A (en) * 1988-08-03 1992-12-01 New England Deaconess Hospital Corporation Hirudin-coated biocompatible substance
AU7749491A (en) 1990-04-23 1991-11-11 Rijksuniversiteit Te Utrecht Cyclic peptides and their use
ES2204944T3 (es) 1994-03-03 2004-05-01 Alexion Pharmaceuticals, Inc. Genes y proteinas de fusion inhibidores del complemento terminal.
US5776970A (en) * 1994-04-28 1998-07-07 Yeda Research And Development Co. Ltd. Tryptophan derivatives as protein tyrosine kinase blockers and their use in the treatment of neoplastic diseases
US6319897B1 (en) * 1996-03-13 2001-11-20 John D. Lambris Peptides which inhibit complement activation
US6221621B1 (en) * 1997-03-06 2001-04-24 Bard Diagnostic Sciences, Inc. Methods of screening for colorectal cancers in which a complement Factor I or related protein is associated
US6169057B1 (en) 1997-09-04 2001-01-02 The Regents Of The University Of California Use of tryptophan and analogs as plant growth regulators
WO1999013899A1 (en) 1997-09-17 1999-03-25 Trustees Of The University Of Pennsylvania Peptides and peptidomimetics for inhibiting complement activation
WO1999052539A1 (en) 1998-04-10 1999-10-21 Mayo Foundation For Medical Education And Research Neo-tryptophan
WO2004026326A2 (en) 2002-09-20 2004-04-01 Stichting Katholieke Universiteit Antigen uptake receptor for candida albicans on dendritic cells
BRPI0617186A2 (pt) * 2005-10-08 2011-07-19 Potentia Pharmaceuticals Inc uso de análogo de compstatina, implante ocular, micropartìcula ou nanopartìcula, composição, composto multivalente, ácido nucléico, vetor de expressão, célula hospedeira recombinante, proteìna de fusão e método de produção e teste
PT1960422E (pt) * 2005-11-28 2012-08-16 Univ Pennsylvania Análogos de compstatina potentes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2238322C2 (ru) * 1996-03-07 2004-10-20 Имутран Лимитед Протеин, обладающий способностью к образованию с3-конвертазы, днк, вектор, конъюгат и их использование
WO2004026328A1 (en) * 2002-09-20 2004-04-01 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved activity

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DENNIS MARK S ET AL: "Albumin binding as a general strategy for improving the pharmacokinetics of proteins." THE JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, vol.277, no.38, pages 35035-35043. *
KATRAGADDA ET AL: "Structure-activity-based design of potent compstatin analogs" MOLECULAR IMMUNOLOGY, 2006, vol.44, no.1-3, page 192. *
KATRAGADDA MADAN ET AL: "Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin." JOURNAL OF MEDICINAL CHEMISTRY, 2006, vol.49, no.15, pages 4616-4622. *
KATRAGADDA MADAN ET AL: "Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin." JOURNAL OF MEDICINAL CHEMISTRY, 2006, vol.49, no.15, pages 4616-4622. KATRAGADDA ET AL: "Structure-activity-based design of potent compstatin analogs" MOLECULAR IMMUNOLOGY, 2006, vol.44, no.1-3, page 192. DENNIS MARK S ET AL: "Albumin binding as a general strategy for improving the pharmacokinetics of proteins." THE JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, vol.277, no.38, pages 35035-35043. *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10407466B2 (en) 2005-10-08 2019-09-10 Apellis Pharmaceuticals, Inc. Methods of selecting compstatin mimetics
US11001610B2 (en) 2011-05-11 2021-05-11 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
US10125171B2 (en) 2011-05-11 2018-11-13 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
US11661441B2 (en) 2011-05-11 2023-05-30 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
US11292815B2 (en) 2012-11-15 2022-04-05 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
US10875893B2 (en) 2012-11-15 2020-12-29 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
RU2705215C2 (ru) * 2012-11-15 2019-11-06 Апеллис Фармасьютикалс, Инк. Клеточно-реактивные аналоги компстатина, аналоги компстатина длительного действия или аналоги компстатина нацеленного действия и связанные с ними композиции и способы
US10035822B2 (en) 2012-11-15 2018-07-31 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
US10941184B2 (en) 2013-03-15 2021-03-09 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
US10308687B2 (en) 2013-03-15 2019-06-04 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
US11407789B2 (en) 2013-03-15 2022-08-09 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
US11903994B2 (en) 2015-10-07 2024-02-20 Apellis Pharmaceuticals, Inc. Dosing regimens
US11338013B2 (en) 2016-10-17 2022-05-24 Apellis Pharmaceuticals, Inc. Combination therapy for C3 inhibition
US11040107B2 (en) 2017-04-07 2021-06-22 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
US11844841B2 (en) 2017-04-07 2023-12-19 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
US11510939B1 (en) 2019-04-19 2022-11-29 Apellis Pharmaceuticals, Inc. RNAs for complement inhibition

Also Published As

Publication number Publication date
CN102977191B (zh) 2016-08-10
JP2013177403A (ja) 2013-09-09
US20190016758A1 (en) 2019-01-17
WO2007062249A3 (en) 2007-09-13
PT1960422E (pt) 2012-08-16
CA2631443C (en) 2017-09-19
EP2377878B1 (en) 2018-03-28
CN101400692A (zh) 2009-04-01
CN102977191A (zh) 2013-03-20
AU2006318333A1 (en) 2007-05-31
CA2631443A1 (en) 2007-05-31
ES2677619T3 (es) 2018-08-03
EP2377877B1 (en) 2018-03-28
US20080227717A1 (en) 2008-09-18
BRPI0619023A2 (pt) 2011-09-20
RS52429B (en) 2013-02-28
EP1960422A2 (en) 2008-08-27
DK1960422T3 (da) 2012-08-13
EP2377877A1 (en) 2011-10-19
IL237915B (en) 2018-11-29
CN106188239B (zh) 2020-01-07
RU2012147267A (ru) 2014-05-20
US20120004393A1 (en) 2012-01-05
WO2007062249A2 (en) 2007-05-31
CA2971349A1 (en) 2007-05-31
US7888323B2 (en) 2011-02-15
CA2971349C (en) 2020-09-08
PL1960422T3 (pl) 2012-11-30
ES2390828T3 (es) 2012-11-16
CN101400692B (zh) 2013-01-02
CN106188239A (zh) 2016-12-07
HRP20120621T1 (hr) 2012-09-30
EP1960422B1 (en) 2012-05-30
ES2677947T3 (es) 2018-08-07
IL191674A0 (en) 2009-02-11
HK1124621A1 (en) 2009-07-17
JP2009517476A (ja) 2009-04-30
RU2008126232A (ru) 2010-01-10
BRPI0619023B1 (pt) 2022-09-27
JP5927139B2 (ja) 2016-05-25
RU2656102C2 (ru) 2018-05-31
US20170305971A1 (en) 2017-10-26
EP2377878A1 (en) 2011-10-19
EP3363810A1 (en) 2018-08-22
IL191674A (en) 2015-04-30
JP5302004B2 (ja) 2013-10-02
US9169307B2 (en) 2015-10-27
US20160096866A1 (en) 2016-04-07

Similar Documents

Publication Publication Date Title
RU2656102C2 (ru) Эффективные аналоги компстатина
JP4614222B2 (ja) 改善された活性を有するコンプスタチン（Ｃｏｍｐｓｔａｔｉｎ）類似体
AU2016202286B2 (en) Potent compstatin analogs
AU2006318333B2 (en) Potent compstatin analogs